|
See related Bondronat information |
|
|
|
Manufacturer |
Roche |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Ibandronic acid |
|
Indications |
Prevention of skeletal events in patients w/ breast cancer & bone metastases. Vial Treatment of tumour-induced hypercalcaemia w/ or w/o metastases. |
|
Dosage |
Tab 1 tab daily. Vial Prevention of skeletal events in patients w/ breast cancer & bone metastases 6 mg IV infused over 15 min every 3-4 wk. Treatment of tumour-induced hypercalcaemia Adult & elderly 2-4 mg. |
|
Administration |
Should be taken on an empty stomach (Must be taken at least 30 min before the 1st food, drink or medication of the day. Take w/ a full glass of only plain water upon arising for the day & remain in sitting/upright position for at least 1 hr. Do not lie down, eat/drink anything except plain water or take other oral medicines for at least 30 min. Swallow whole, do not chew/crush/suck.). |
|
Contraindications |
Hypersensitivity to bisphosphonates. |
|
Special Precautions |
Pregnancy & lactation. Treat hypocalcaemia before initiating therapy. Tab: Alert to signs or symptoms signalling possible oesophageal reaction. Concomitant use w/ NSAIDs. Patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Vial: Overhydration in patients at risk of heart failure. Osteonecrosis of the jaw. Perform dental exam before initiating treatment & avoid invasive dental procedure while on treatment. |
|
Adverse Drug Reactions |
Hypocalcemia, GI disorders. Tab: Oesophagitis, asthenia. Vial: Flu-like syndrome.
View ADR Monitoring Form |
|
Drug Interactions |
Aminoglycosides, Ca & other multivalent cations.
View more drug interactions with Bondronat |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
